Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 12-Month Low - Time to Sell?

Syndax Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Syndax Pharmaceuticals hit a new 52-week low of $8.41, trading around $8.52; its 50- and 200-day moving averages were $14.60 and $19.56, respectively.
  • Analysts maintain a “Moderate Buy” consensus, with an average price target of $41.60; 10 analysts rate the stock Buy and one rates it Sell.
  • In its latest quarter, Syndax reported an adjusted loss of $0.55 per share, missing estimates of $0.50, while revenue of $83.3 million topped forecasts and increased 81.9% year over year.
  • Five stocks to consider instead of Syndax Pharmaceuticals.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $8.41 and last traded at $8.52, with a volume of 44,188 shares. The stock had previously closed at $8.56.

Wall Street Analyst Weigh In

SNDX has been the topic of several research reports. Weiss Ratings raised Syndax Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, November 3rd. Bank of America reiterated a "buy" rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. JPMorgan Chase & Co. dropped their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. HC Wainwright reduced their price target on Syndax Pharmaceuticals from $38.00 to $36.00 and set a "buy" rating for the company in a research note on Tuesday, November 3rd. Finally, UBS Group restated a "buy" rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.60.

View Our Latest Stock Report on SNDX

Syndax Pharmaceuticals Trading Up 2.8%

The company has a quick ratio of 4.37, a current ratio of 4.69 and a debt-to-equity ratio of 38.95. The firm has a market capitalization of $792.26 million, a P/E ratio of -3.73 and a beta of 0.48. The firm has a 50 day moving average of $14.60 and a 200-day moving average of $19.56.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.05). The company had revenue of $83.30 million for the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative return on equity of 804.38% and a negative net margin of 72.32%. Syndax Pharmaceuticals's revenue was up 81.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.70) EPS. On average, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.09 earnings per share for the current fiscal year.

Insider Activity at Syndax Pharmaceuticals

In related news, Director Dennis Podlesak sold 8,000 shares of the firm's stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the transaction, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of large investors have recently bought and sold shares of SNDX. Allworth Financial LP bought a new position in Syndax Pharmaceuticals in the 2nd quarter valued at about $26,000. Sterling Capital Management LLC raised its position in shares of Syndax Pharmaceuticals by 846.6% in the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company's stock valued at $56,000 after buying an additional 2,650 shares in the last quarter. Nykredit A S bought a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $72,000. Integrated Wealth Concepts LLC bought a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $73,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $86,000.

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company's medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines